Vol.24, No.1, 2022, pp.101-111, doi:10.32604/oncologie.2022.020357
OPEN ACCESS
ARTICLE
Exploration of Combinational Therapeutic Strategies for HCC Based on TCGA HCC Database
  • Dong Yan1,#, Chunxiao Li2,#, Yantong Zhou2, Xue Yan1, Weihua Zhi1, Haili Qian2,*, Yue Han1,*
1 Department of Interventional Therapy, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
2 State Key Laboratory of Molecular Oncology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
* Corresponding Authors: Haili Qian. Email: ; Yue Han. Email:
# These authors contributed equally to this work
Received 18 November 2021; Accepted 14 February 2022; Issue published 31 March 2022
Abstract
Hepatocellular carcinoma (HCC) is one of the most deadly types of cancer. Sorafenib is currently the only available first-line molecular targeted drug approved by the FDA for HCC. However, primary and secondary resistance is often encountered with treatment with sorafenib. Genomic alterations found in HCC represent potential targets to develop new drugs or new combinational strategies against this type of cancer. Here we analyzed genomic alterations from the TCGA database of HCC samples and the corresponding targeted drugs available to the clinic to identify candidate drugs that might hold promise when used in combination with sorafenib. Our results revealed that IL6, JAK1, LEPR and RAF1 related pathways were commonly altered in HCC, which have targeted drugs available in medical practice. Fourteen genes with available targeting drugs were frequently altered in HCC. The pathways and gene targets with the respective targeted drugs warrant further evaluation in clinical trials to determine their therapeutic value in the treatment of HCC, alone or in combination with sorafenib. In summary, the analysis of TCGA, identified a series of pathways with targeted drugs available that were altered in HCC. Combination treatment with specific targeted drugs, depending on the altered pathways found in individuals may provide a better treatment strategy that will ultimately improve individual patient survival.
Keywords
Hepatocellular carcinoma; TCGA database; sorafenib; combinational treatment; targeting drug
Cite This Article
Yan, D., Li, C., Zhou, Y., Yan, X., Zhi, W. et al. (2022). Exploration of Combinational Therapeutic Strategies for HCC Based on TCGA HCC Database. Oncologie, 24(1), 101–111.
This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.